Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionLPL Financial LLC
Latest Disclosed Ownership43,925 shares
Latest Disclosed Value $ 5,786,706
LPL Financial LLC reports 8.93% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 6, 2026 - LPL Financial LLC filed a 13F-HR form disclosing ownership of 43,925 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $5,786,706 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 40,323 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 8.93% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 43,925 3,602 8.93 5,787 1.17 0.0015
2026-02-11 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,323 6,133 17.94 5,719 19.17 0.0016
2025-11-12 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,190 4,520 15.23 4,800 28.69 0.0014
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 29,670 13,355 81.86 3,729 106.71 0.0012
2025-05-07 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,315 -439 -2.62 1,804 -21.08 0.0007
2025-02-11 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,754 3,643 27.79 2,287 51.39 0.0009
2024-11-08 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,111 783 6.35 1,511 -11.02 0.0007
2024-08-07 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,328 -232 -1.85 1,697 -2.02 0.0008
2024-05-10 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,560 2,733 27.81 1,732 33.85 0.0009
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,827 13 0.13 1,295 17.21 0.0008
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,814 1,600 19.48 1,104 42.64 0.0008
2023-07-31 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,214 21 0.26 775 -6.63 0.0006
2023-05-10 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,193 -3,016 -26.91 829 -38.04 0.0006
2023-02-07 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,209 -4,278 -27.62 1,339 -18.66 0.0011
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,487 -1,481 -8.73 1,645 -0.54 0.0016
2022-08-12 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,968 -1,157 -6.38 1,654 -2.65 0.0016
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,125 -1,298 -6.68 1,699 2.72 0.0015
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,423 -1,384 -6.65 1,654 -17.13 0.0014
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,807 6,644 46.91 1,996 44.85 0.0019
2021-08-13 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,163 7,654 117.59 1,378 117.69 0.0014
2021-05-14 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,509 -2,035 -23.82 633 -22.71 0.0007
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,544 690 8.79 819 8.48 0.0011
2020-11-09 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,854 1,670 27.01 755 0.13 0.0012
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,184 386 6.66 754 50.20 0.0013
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,798 -201 -3.35 502 -22.17 0.0011
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,999 2,614 77.22 645 111.48 0.0012
2019-11-13 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,385 -217 -6.02 305 0.33 0.0006
2019-08-09 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,602 -949 -20.85 304 -24.19 0.0006
2019-05-08 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,551 657 16.87 401 44.24 0.0009
2019-02-07 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,894 3,894 -80.23 278 37.62 0.0007
2014-02-13 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -19,699 -100.00 0 -100.00
2013-11-04 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,699 19,699 202 0.0013
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.